@article{ATM24280,
author = {Jun Gong and Joseph Chao},
title = {When survival curves cross: are we at a crossroads of immunotherapy in gastric cancer?},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 1},
year = {2019},
keywords = {},
abstract = {The first U.S. Food and Drug Administration (FDA) approval of a programmed cell death protein (PD-1) inhibitor specifically for advanced gastroesophageal cancer occurred with the passing of pembrolizumab on September 22, 2017 (1).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/24280}
}